Beyond Air, Inc. (XAIR) reports Q1 2026 earnings with 107% revenue growth to $7.7M and strategic initiatives for future expansion.

Key Takeaways

• Revenue surged by 107% year-over-year to $7.7 million for fiscal year ended March 31, 2026.
• Customer renewal rate stood at an impressive 90%, highlighting strong customer satisfaction and retention.
• Company is preparing for a potential launch of the second-generation LungFit system by the end of 2026, which could expand the total addressable market to over $1 billion globally.
• Operating expenses were reduced significantly, with R&D expenses down 39% and SGA expenses down 27% compared to the previous fiscal year.
• Guidance for calendar year 2026 revenue is set at $8 million, reflecting 15% growth over the previous year.

Financial Performance

Beyond Air, Inc. reported a remarkable financial performance for the fiscal year ended March 31, 2026. The company achieved a revenue increase of 107%, reaching $7.7 million, compared to $3.7 million in the fiscal year 2025. This growth can be attributed to increased demand for the LungFit PH system, driven by both existing customer retention and the adoption of new hospital clients.

The gross profit for the fiscal year displayed a significant turnaround, improving by $300,000 from a loss of $1.7 million in the prior year, marking a $2 million swing to profitability. This positive trend indicates the operational leverage the company is starting to experience as revenues scale.

Operating expenses also saw substantial reductions, with R&D costs decreasing by 39% to $10.2 million, primarily due to decreased employee expenses from prior restructuring and lower development costs for the upcoming second-generation device. Selling, General, and Administrative (SGA) expenses decreased by 27%, totaling $19.1 million. The company effectively cut its overall cost structure, resulting in a $15.5 million improvement in operating results. However, the net loss attributable to common stockholders was $33.2 million, or $4.01 per share, compared to a loss of $46.6 million, or $13.77 per share, in the previous fiscal year.

Strategic Initiatives

The earnings call highlighted significant strategic initiatives aimed at positioning the company for future growth. One of the most notable developments is the anticipated approval of the second-generation LungFit system, known as Gentoo, which is currently under FDA review. The new device is expected to address transport limitations, potentially increasing the U.S. addressable market by fourfold, from $100 million to $400 million, and expanding the global market opportunity to over $1 billion.

The company has also made strides in expanding its commercial reach, recently securing a national purchasing agreement with one of the top group purchasing organizations (GPOs) for inhaled nitric oxide therapy. This agreement marks the third major GPO partnership, enabling Beyond Air to access a substantial portion of the U.S. market. These partnerships, combined with existing agreements with Premier and Vizient, are expected to play a crucial role in driving customer adoption and revenue growth.

Additionally, Beyond Air has broadened its global distribution network and now holds regulatory clearance in over 45 countries, providing ample opportunities for future revenue generation, even as the company remains in the early stages of international commercialization.

Future Outlook

Looking ahead, management has provided encouraging guidance for calendar year 2026, projecting revenues of $8 million, representing approximately 15% growth over calendar year 2025. Additionally, the company has offered first-time guidance for calendar year 2027, estimating revenues between $16 million and $18 million, which translates to over 110% year-over-year growth at the midpoint of that range, contingent on the anticipated FDA approval and commercial launch of the second-generation system.

Management expressed high confidence in the potential of the Gentoo platform, emphasizing its innovative features, including a smaller footprint, reduced weight, and capabilities for ground and air transport. These advancements are expected to significantly enhance market competitiveness and customer appeal.

Closing Assessment

Overall, Beyond Air, Inc. is at a pivotal juncture, marked by strong revenue growth, strategic advancements in product development, and effective cost management. The company’s focus on aligning its resources for maximum impact, particularly in preparation for the Gentoo system launch, places it in a robust position for future success. With a strong customer retention rate and expanding market access through strategic partnerships, Beyond Air is well-poised to capitalize on emerging opportunities in the nitric oxide market.

This analysis is based on public earnings call materials and is not investment advice.